Negative impact of bone-marrow-derived mesenchymal stem cells on dextran sulfate sodium-induced colitis

World Journal of Gastroenterology

Volumn 21, Issue 7, 2015, Pages 2030-2039

  Nam, Young Sun ^a   Kim, Nayoun ^a   Im, Keon Il ^a   Lim, Jung Yeon ^a   Lee, Eun Sol ^a   Cho, Seok Goo ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Crohn's disease; Dextran sulfate sodium; Inflammatory bowel disease; Mesenchymal stem cells; Ulcerative colitis

Indexed keywords

DEXTRAN SULFATE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; AUTACOID; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BODY WEIGHT; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; MESENCHYMAL STEM CELL; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCORING SYSTEM; SPLEEN; SURVIVAL RATE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COLITIS; COLON; DISEASE MODEL; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHENOTYPE; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE; TIME FACTOR;

ANIMALS; CELLS, CULTURED; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION MEDIATORS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; PHENOTYPE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TIME FACTORS;

EID: 84922727033     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i7.2030     Document Type: Article

References (49)

1. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-466 [PMID: 18500230 DOI: 10.1038/nri2340]
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
3. Dexter TM, Spooncer E, Schofield R, Lord BI, Simmons P. Haemopoietic stem cells and the problem of self-renewal. Blood Cells 1984; 10: 315-339 [PMID: 6543654]
4. Imaeda T. Ultrastructure of L-phase variants isolated from a culture of Mycobacterium phlei. J Med Microbiol 1975; 8: 389-395 [PMID: 1177288]
5. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells 2007; 25: 2896-2902 [PMID: 17901396 DOI: 10.1634/stemcells.2007-0637]
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147 [PMID: 10102814]
7. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, Freeman TB, Saporta S, Janssen W, Patel N, Cooper DR, Sanberg PR. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000; 164: 247-256 [PMID: 10915564 DOI: 10.1006/exnr.2000.7389]
8. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011; 6: 457-478 [PMID: 21073342 DOI: 10.1146/annurev-pathol-011110-130230]
9. Ko IK, Kim BG, Awadallah A, Mikulan J, Lin P, Letterio JJ, Dennis JE. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 2010; 18: 1365-1372 [PMID: 20389289 DOI: 10.1038/mt.2010.54]
10. He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci 2012; 57: 3136-3144 [PMID: 22752635 DOI: 10.1007/s10620-012-2290-5]
11. Kim DJ, Kim KS, Song MY, Seo SH, Kim SJ, Yang BG, Jang MH, Sung YC. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa. Clin Immunol 2012; 144: 190-199 [PMID: 22836084 DOI: 10.1016/j.clim.2012.06.009]
12. Parekkadan B, Fletcher AL, Li M, Tjota MY, Bellemare-Pelletier A, Milwid JM, Lee JW, Yarmush ML, Turley SJ. Aire controls mesenchymal stem cell-mediated suppression in chronic colitis. Mol Ther 2012; 20: 178-186 [PMID: 21952165 DOI: 10.1038/mt.2011.192]
13. Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant 2013; 22: 279-285 [PMID: 23006344 DOI: 10.3727/096368912X656045]
14. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-798 [PMID: 21257987 DOI: 10.1136/gut.2010.214841]
15. de la Portilla F, Alba F, García-Olmo D, Herrerías JM, González FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013; 28: 313-323 [PMID: 23053677 DOI: 10.1007/s00384-012-1581-9]
16. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48: 1416-1423 [PMID: 15933795 DOI: 10.1007/s10350-005-0052-6]
17. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52: 79-86 [PMID: 19273960 DOI: 10.1007/DCR.0b013e3181973487]
18. Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 2012; 27: 595-600 [PMID: 22065114 DOI: 10.1007/s00384-011-1350-1]
19. Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum 2012; 55: 762-772 [PMID: 22706128 DOI: 10.1097/DCR.0b013e318255364a]
20. Lee WY, Park KJ, Cho YB, Yoon SN, Song KH, Kim do S, Jung SH, Kim M, Yoo HW, Kim I, Ha H, Yu CS. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells 2013; 31: 2575-2581 [PMID: 23404825 DOI: 10.1002/stem.1357]
21. Bouffi C, Bony C, Courties G, Jorgensen C, Noël D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010; 5: e14247 [PMID: 21151872 DOI: 10.1371/journal.pone.0014247]
22. Chen B, Hu J, Liao L, Sun Z, Han Q, Song Z, Zhao RC. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol 2010; 159: 292-302 [PMID: 20002448 DOI: 10.1111/j.1365-2249.2009.04069.x]
23. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60: 1006-1019 [PMID: 19333946 DOI: 10.1002/art.24405]
24. Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Guo J, Yu P, Li C, Liu X, Huang Z, Wang D, Li H, Gu Z, Liu B, Li Z. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010; 12: R210 [PMID: 21080925 DOI: 10.1186/ar3187]
25. Park MJ, Park HS, Cho ML, Oh HJ, Cho YG, Min SY, Chung BH, Lee JW, Kim HY, Cho SG. Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 2011; 63: 1668-1680 [PMID: 21384335 DOI: 10.1002/art.30326]
26. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010; 12: R31 [PMID: 20175883 DOI: 10.1186/ar2939]
27. Lee JH, Jeon EJ, Kim N, Nam YS, Im KI, Lim JY, Kim EJ, Cho ML, Han KT, Cho SG. The synergistic immunoregulatory effects of culture-expanded mesenchymal stromal cells and CD4(+)25(+)Foxp3+ regulatory T cells on skin allograft rejection. PLoS One 2013; 8: e70968 [PMID: 23940676 DOI: 10.1371/journal.pone.0070968]
28. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med 2013; 45: e2 [PMID: 23306700 DOI: 10.1038/emm.2013.2]
29. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843 [PMID: 11986244]
30. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160 [PMID: 19210524 DOI: 10.1111/j.1365-2249.2009.03874.x]
31. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827 [PMID: 15591115 DOI: 10.1182/blood-2004-09-3696]
32. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577 [PMID: 16293599 DOI: 10.1182/blood-2005-07-2793]
33. Kim N, Im KI, Lim JY, Jeon EJ, Nam YS, Kim EJ, Cho SG. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 2013; 92: 1295-1308 [PMID: 23722500 DOI: 10.1007/s00277-013-1796-z]
34. Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 2011; 33: 593-602 [PMID: 21499984 DOI: 10.1007/s00281-011-0267-7]
35. Dazzi F, Marelli-Berg FM. Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. Eur J Immunol 2008; 38: 1479-1482 [PMID: 18493977 DOI: 10.1002/eji.200838433]
36. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398 [PMID: 16123384 DOI: 10.1634/stemcells.2005-0008]
37. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755 [PMID: 18493986 DOI: 10.1002/eji.200738129]
38. Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, Cho CS. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008; 153: 269-276 [PMID: 18713142 DOI: 10.1111/j.1365-2249.2008.03683.x]
39. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noël D. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005; 52: 1595-1603 [PMID: 15880818 DOI: 10.1002/art.21012]
40. Eljaafari A, Tartelin ML, Aissaoui H, Chevrel G, Osta B, Lavocat F, Miossec P. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum 2012; 64: 2147-2157 [PMID: 22275154 DOI: 10.1002/art.34391]
41. Guo Z, Zheng C, Chen Z, Gu D, Du W, Ge J, Han Z, Yang R. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur J Immunol 2009; 39: 2840-2849 [PMID: 19637224 DOI: 10.1002/eji.200839070]
42. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238 [PMID: 16648838 DOI: 10.1038/nature04753]
43. Park JS, Park MK, Lee SY, Oh HJ, Lim MA, Cho WT, Kim EK, Ju JH, Park YW, Park SH, Cho ML, Kim HY. TWEAK promotes the production of Interleukin-17 in rheumatoid arthritis. Cytokine 2012; 60: 143-149 [PMID: 22819243 DOI: 10.1016/j.cyto.2012.06.285]
44. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-189 [PMID: 16473830 DOI: 10.1016/j.immuni.2006.01.001]
45. Svobodova E, Krulova M, Zajicova A, Pokorna K, Prochazkova J, Trosan P, Holan V. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012; 21: 901-910 [PMID: 21663543 DOI: 10.1089/scd.2011.0157]
46. Kim N, Cho SG. Clinical applications of mesenchymal stem cells. Korean J Intern Med 2013; 28: 387-402 [PMID: 23864795 DOI: 10.3904/kjim.2013.28.4.387]
47. Lim JY, Park MJ, Im KI, Kim N, Jeon EJ, Kim EJ, Cho ML, Cho SG. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model. Cell Transplant 2014; 23: 703-714 [PMID: 23452894 DOI: 10.3727/096368913X664577]
48. Im KI, Park MJ, Kim N, Lim JY, Park HS, Lee SH, Nam YS, Lee ES, Lee JH, Cho ML, Cho SG. Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance. Stem Cells Dev 2014; 23: 2364-2376 [PMID: 24804993 DOI: 10.1089/scd.2013.0617]
49. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58: 929-939 [PMID: 19136511 DOI: 10.1136/gut.2008.168534]